Sentence examples similar to regimen progression from inspiring English sources

Main effect = main effect of Regimen group; Progression = interaction of regimen group with Change at Progression; Proximity = interaction of regimen group with Change with Proximity to Progression.

One-third of the population was considered anthracycline-resistant (relapse within 1 year after the end of adjuvant anthracycline-based regimen or progression after response or stabilization for palliative treatment) and two patients were anthracycline-refractory (progression on adjuvant therapy or as a best response during palliative treatment).

After 6 cycles, oxaliplatin was discontinued and patients continued to receive bevacizumab and capecitabine following the same regimen until progression or study discontinuation.

A subgroup analysis of response was performed according to the time elapsed between the end of treatment with the taxane-containing regimen and progression.

A fourth study – a retrospective analysis of 101 patients who continued to receive a trastuzumab-containing regimen beyond progression – was reported this year [ 45].

Evaluation following two courses of a dacarbazine-based regimen showed progression of the cutaneous lesions and new metastases in both the lung parenchyma and mediastinal lymph nodes.

Indeed, KRAS and PIK3CA mutations were not associated with worse OS, possibly because 82% of patients received another regimen after progression on cetuximab-based treatment or because response to cetuximab impacts modestly on the natural history of mCRC.

In the European Cohort, among the 170 HIV-2 infected patients enrolled (44 on three NRTIs), one patient (2%) receiving a triple NRTI regimen experienced progression to AIDS (tuberculosis) five months after treatment initiation.

These preliminary efficacy results suggest that the combination of MK-2206 witrastuzumabmay may offer patients an effective salvage regimen following progression on trastuzumab, or may prevent or delay clinical resistance if used earlier in the disease.

It is possible that poor median OS in our FOLFIRI arm is due to the fact that only 62% of patients in this arm received an oxaliplatin-based second line regimen at progression of the disease.

Moreover, the survival of patients receiving all active drugs upfront (FOLFOXIRI patients) was similar with that of patients receiving the active drugs in sequence (i.e. FOLOFIRI first and L-OHP-based regimen on progression).